Phase 3 Donor Clinical Trials
5 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–5 of 5 trials
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation
End Stage Renal DiseaseDelayed Graft FunctionDeceased Donor Kidney Transplant
Apellis Pharmaceuticals, Inc.320 enrolled1 locationNCT07020832
Recruiting
Phase 3
Anesthesia sTrategy foR Organ Procurement In braiN dEath
Brain-dead Organ Donors
University Hospital, Grenoble270 enrolled1 locationNCT07166991
Completed
Phase 3
Better Evidence for Selecting Transplant Fluids (BEST-Fluids)
Delayed graft function in deceased donor kidney recipients.
Australasian Kidney Trials Network (University of Qld)800 enrolled15 locationsACTRN12617000358347
Active
Phase 3
Monitoring of iron status and clinical evaluation of interventions intended to maintain clinically adequate iron status in women who are new blood donors
Prevention of low iron status and iron deficiency in new female blood donors
Dr James M Faed5,100 enrolled1 locationACTRN12612000911897
Completed
Phase 3
A randomised, double blind, placebo controlled trial of the effectiveness of “post donation” short term iron replacement in female whole blood donors with a daily oral dose of 45 mgs elemental iron
Iron deficiency in female blood donors aged 18-45 years
Australian Red Cross Blood Service260 enrolled1 locationACTRN12609000496213